Les effets secondaires des anti-angiogéniques (à l'exception des effets cutanés) : Actualités et perspectives dans le cancer du rein = Side effects of anti-angiogenics (not including cutaneous effects)CHEVREAU, C.Oncologie (Paris). 2009, Vol 11, Num 5, pp 285-290, issn 1292-3818, 6 p.Article

Traitement standard des formes de mauvais pronostic : chimiothérapie conventionnelle = Conventional chemotherapy of high risk testicular cancerCHEVREAU, C.Pathologie et biologie. 1994, Vol 42, Num 10, pp 992-993, issn 0369-8114Conference Paper

Deuxième ligneGUILLOT, A; CHEVREAU, C.Correspondances en onco-urologie. 2014, Vol 5, Num 2, pp 72-74, issn 2110-087X, 3 p.Article

EXPERIENCE DE LA VENTILATION SPONTANEE EN PRESSION EXPIRATOIRE POSITIVE EN REANIMATION CHIRURGICALE POLYVALENTEPICARD JM; JACOB F; CHEVREAU C et al.1981; ANN. ANESTHESIOL. FR.; ISSN 0003-4061; FRA; DA. 1981; VOL. 22; NO 5; PP. 423-427; BIBL. 27 REF.Conference Paper

Prise en charge du tératome pur testiculaire postpubertaire à propos d'une série multicentrique sur 15 ans = Management of pure teratoma of the testis in adult, results of a multicenter study over 15 yearsLABARTHE, P; KHEDIS, M; HOULGATTE, A et al.Progrès en urologie (Paris). 2008, Vol 18, Num 13, pp 1075-1081, issn 1166-7087, 7 p.Article

Refining the optimal chemotherapy regimen for good-risk metastatic nonseminomatous germ-cell tumors : a randomized trial of the Genito-Urinary Group of the French Federation of Cancer Centers (GETUG T93BP)CULINE, S; KERBRAT, P; BIRON, P et al.Annals of oncology. 2007, Vol 18, Num 5, pp 917-924, issn 0923-7534, 8 p.Article

Prognostic factors of survival and rapid progression in 782 patients with metastatic renal carcinomas treated by cytokines: a report from the Groupe Français d'ImmunothérapieNEGRIER, S; ESCUDIER, B; GOMEZ, F et al.Annals of oncology. 2002, Vol 13, Num 9, pp 1460-1468, issn 0923-7534, 9 p.Article

Cytokines in metastatic renal cell carcinoma : Is it useful to switch to Interleukin-2 or interferon after failure of a first treatment?ESCUDIER, B; CHEVREAU, C; SAVARY, J et al.Journal of clinical oncology. 1999, Vol 17, Num 7, pp 2039-2043, issn 0732-183XArticle

Population pharmacokinetics of total and unbound etoposideNGUYEN, L; CHATELUT, E; CHEVREAU, C et al.Cancer chemotherapy and pharmacology. 1998, Vol 41, Num 2, pp 125-132, issn 0344-5704Article

Subcutaneous interleukin-2, interferon alfa-2a, and continuous infusion of fluorouracil in metastatic renal cell carcinoma : A multicenter phase II trialRAVAUD, A; AUDHUY, B; LINASSIER, C et al.Journal of clinical oncology. 1998, Vol 16, Num 8, pp 2728-2732, issn 0732-183XArticle

A pharmacogically guided phase I study of carboplatin in combination with methotrexate and vinblastine in advanced urothelial cancerCHATELUT, E; CHEVREAU, C; BRUNNER, V et al.Cancer chemotherapy and pharmacology. 1995, Vol 35, Num 5, pp 391-396, issn 0344-5704Article

Prediction of carboplatin clearance from standard morphological and biological patient characteristicsCHATELUT, E; CANAL, P; BRUNNER, V et al.Journal of the National Cancer Institute. 1995, Vol 87, Num 8, pp 573-580, issn 0027-8874Article

Early intensified chemotherapy with autologous bone marrow transplantation in first line treatment of poor risk non-seminomatous germ cell tumours : preliminary results of a French randomized trial. DiscussionCHEVREAU, C; DROZ, J. P; BOUZY, J et al.CHEVREAU, C; European urology. 1993, Vol 23, Num 1, pp 213-218, issn 0302-2838Conference Paper

Cardiotoxicity of high-dose continuous infusion fluorouracil : a prospective clinical studyDE FORNI, M; MALET-MARTINO, M. C; ROCHE, H et al.Journal of clinical oncology. 1992, Vol 10, Num 11, pp 1795-1801, issn 0732-183XArticle

Evaluation du risque iatrogène létal en milieu cancérologique = Evaluation of iatrogenic letal risk in chemotherapy of neoplastic diseasesSORBETTE, F; ROCHE, H; CHEVREAU, C et al.Thérapie (Paris). 1989, Vol 44, Num 5, issn 0040-5957, 379 [1 p.]Article

Place de la radiothérapie dans le traitement conservateur des sarcomes en territoire irradié = Radiotherapy as conservative therapy for sarcomas within irradiated fieldMODESTO, A; FILLERON, T; CHEVREAU, C et al.Cancer radiothérapie. 2014, Vol 18, Num 3, pp 171-176, issn 1278-3218, 6 p.Article

High-dose chemotherapy consolidation for chemosensitive advanced soft tissue sarcoma patients: an open-label, randomized controlled trialBUI-NGUYEN, B; RAY-COQUARD, I; THYSS, A et al.Annals of oncology. 2012, Vol 23, Num 3, pp 777-784, issn 0923-7534, 8 p.Article

Imatinib for progressive and recurrent aggressive fibromatosis (desmoid tumors): an FNCLCC/French Sarcoma Group phase II trial with a long-term follow-upPENEL, N; LE CESNE, A; JIMENEZ, M et al.Annals of oncology. 2011, Vol 22, Num 2, pp 452-457, issn 0923-7534, 6 p.Article

First-line bevacizumab combined with reduced dose interferon-a2a is active in patients with metastatic renal cell carcinomaMELICHAR, B; KORALEWSKI, P; NEGRIER, S et al.Annals of oncology. 2008, Vol 19, Num 8, pp 1470-1476, issn 0923-7534, 7 p.Article

Granulocyte-macrophage colony-stimulating factor alone or with dacarbazine in metastatic melanoma: a randomized phase II trialRAVAUD, A; DELAUNAY, M; CHEVREAU, C et al.British journal of cancer. 2001, Vol 85, Num 10, pp 1467-1471, issn 0007-0920Article

Phase I-II trial of intensification of the MAID regimen with support of lenograstim (rHuG-CSF) in patients with advanced soft-tissue sarcoma (STS)CHEVREAU, C; BINH NGUYEN BUI; CHEVALLIER, B et al.American journal of clinical oncology. 1999, Vol 22, Num 3, pp 267-272, issn 0277-3732Article

Phase II study of Interferon-α and all-trans retinoic acid in metastatic renal cell carcinomaESCUDIER, B; RAVAUD, A; BERTON, D et al.Journal of immunotherapy with emphasis on tumor immunology. 1998, Vol 21, Num 1, pp 62-64, issn 1067-5582Article

Recombinant human interleukin-2, recombinant human interferon alfa-2a, or both in metastatic renal-cell carcinomaNEGRIER, S; ESCUDIER, B; PHILIP, T et al.The New England journal of medicine. 1998, Vol 338, Num 18, pp 1272-1278, issn 0028-4793Article

Le cancer du rein de l'adulte = Adult renal cell carcinomaDELORD, J.-P; ALEXANDRE, J; CHEVREAU, C et al.Bulletin du cancer. 1998, Vol SEP, pp 4-15, issn 0007-4551, SUP1Article

How to predict carboplatin clearance from standard morphological and biological characteristics in obese patientsBENEZET, S; GUIMBAUD, R; CHATELUT, E et al.Annals of oncology. 1997, Vol 8, Num 6, pp 607-609, issn 0923-7534Article